Sartorius Reports Positive Closing for Fiscal 2024

Sartorius AG, a life science firm based in Göttingen, Germany, concluded fiscal 2024 on a strong note with a very good fourth quarter. The company achieved its full-year guidance, marking sales revenue of 3,381 million euros, maintaining the previous year's level despite industry challenges. Underlying profit margins stood at 28%. Order intake rose by 10.8%, reflecting growing demand in H2 2024.

The company's regional performance varied significantly. EMEA saw a 5.5% revenue increase, while Asia-Pacific recorded a modest growth of 1.4%. However, Americas faced a 6.1% decline due to reduced investments. The Bioprocess Solutions Division showed slight revenue growth of 0.9%, driven by consumables, despite investment hesitancy. Conversely, the Lab Products & Services Division saw a 3% decline in sales.

For 2025, Sartorius predicts moderately profitable growth above market levels with a focus on consumables, amid recovering market demand.